



August 21, 2019
FunPep Co., Ltd.

Announcing Acceptance into NEDO Subsidy Program

— Research and development of antibody-inducing peptides targeting IL-23 —

FunPep Co., Ltd. (“FunPep”) is pleased to announce that our R&D project has been selected by the New Energy and Industrial Technology Development Organization (NEDO) as a "2019 R&D Venture Support Project / Commercialization Support through the Promotion of Translational Research".

< Overview >

Subsidized Project Name	Research and development of antibody-inducing peptides targeting IL-23
Translational Research Institution	Osaka University
Subsidized Company	FunPep Co., Ltd.

FunPep is conducting research and development of antibody-inducing peptides in collaboration with the Osaka University Graduate School of Medicine (Professor Ryuichi Morishita, Department of Clinical Gene Therapy and Professor Hironori Nakagami, Department of Health Development and Medicine), and have established fundamental technologies for the creation of novel antibody-inducing peptides.

In this grant project, FunPep will conduct exploratory research in collaboration with the translational research institution Osaka University on novel antibody-inducing peptides against IL-23, a target related to immunological diseases, using these fundamental technologies and will study manufacturing methods of APIs and formulations for preclinical studies of the selected development compounds.

This grant program is designed to support R&D-oriented ventures that develop business in collaboration with translational research institutions. The eligibility period is from August 19, 2019, to March 31, 2020, with a maximum extension to February 26, 2021. FunPep will receive an amount equivalent to two-thirds of the research and development costs for this grant project.